CABA Cabaletta Bio

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December:

  • 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of management will also be available for one-on-one meetings.



  • Citi’s 2024 Global Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, December 4, 2024, in Miami, FL.

A live webcast of the fireside chat will be available on the News and Events section of the Company’s website at . Replays will be available on the website for 30 days.

About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. CABA-201 is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit  and connect with us on LinkedIn.

Contacts:

Anup Marda

Chief Financial Officer

William Gramig

Precision AQ



EN
26/11/2024

Underlying

CABACabaletta Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cabaletta Bio

 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Participate in Upcoming Investor Conferences in Septe...

Cabaletta Bio to Participate in Upcoming Investor Conferences in September PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025: Webcasted fireside chat at 10:55 a.m. ET on Wednesday, September 3, 2025, in New York, NY. The Compan...

August 27, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provid...

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update – Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gravis – ...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Pricing of Public Offering of Securities

Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in li...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces Proposed Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certa...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patie...

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all imm...

June 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch